<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Psychiatric aspects of organ transplantation</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Psychiatric aspects of organ transplantation</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Psychiatric aspects of organ transplantation</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan M Silver, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David Solomon, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 15, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The development of end-stage organ failure combined with the realization that life may no longer be possible without medical intervention can lead to depression, anxiety, nonadherence with diet or medication, and sexual dysfunction in the transplant patient [<a href="#rid1">1,2</a>]. The administration of immunosuppressive drugs, such as glucocorticoids and calcineurin inhibitors, has also been implicated in causing psychiatric disturbances [<a href="#rid3">3,4</a>]; these include euphoria, delirium, generalized anxiety disorder, and hallucinosis.</p><p>These disorders frequently require treatment with psychopharmacologic agents. However, their administration may be hazardous because of adverse effects as well as specific interactions with immunosuppressive drugs.</p><p>This topic review will discuss some of the more common psychiatric disturbances that develop in transplant recipients with specific attention to their impact upon pharmacologic management and prognosis. Discussions related to psychotherapy are presented separately.</p><p class="headingAnchor" id="H2"><span class="h1">PSYCHOLOGICAL IMPACT OF TRANSPLANTATION</span><span class="headingEndMark"> — </span>The altruistic act of kidney donation appears to confer psychologic benefit to the donor. In a study of donors followed after a period of 5 to 10 years, the majority of individuals, independent of the outcome of the procedure, expressed positive feelings towards having donated a kidney [<a href="#rid3">3</a>]. However, in another survey, donating was perceived to have had a negative impact upon the health and finances of 15 and 23 percent of responding donors, respectively [<a href="#rid4">4</a>]. Despite this perception, donors of kidneys live longer than others, due most probably to the screening process, which only permits healthy persons to be accepted for living kidney donation [<a href="#rid5">5</a>].</p><p>For the graft recipient, transplantation means more than an operation; it requires a certain degree of personal strength and adequate coping skills. In a study of heart transplant recipients, patients were grouped according to their response to a psychological survey [<a href="#rid6">6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients in group 1 denied thinking about the donor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients in group 2 were partial deniers who were aware that they avoided thinking about the donor.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients in group 3 accepted the death of the donor as reality and also reported having more or less close connections with the donor.</p><p></p><p>Eighty two percent of the patients interviewed accepted the donor heart immediately as their own, whereas the remaining 18 percent avoided talking and thinking about the graft and donor. Thus, transplant recipients use different defense mechanisms concerning their transplanted organ to help them cope with their medical condition.</p><p>Kidney recipients also have particular difficulty asking and/or involving a possible living donor. Patients do not pursue living donation in part because of concerns involving and possibly risking the health of a living donor, pain related to the donor surgery, the possibility of kidney rejection, and an inability to ask someone to be a living donor [<a href="#rid7">7,8</a>].</p><p class="headingAnchor" id="H3"><span class="h1">DEPRESSION</span><span class="headingEndMark"> — </span>End-stage kidney disease and transplantation are associated with depression [<a href="#rid9">9</a>], which impacts adversely upon compliance and may be associated with decreased longevity [<a href="#rid10">10-12</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 209 consecutive primary renal allograft recipients, suicide accounted for 15 percent of deaths at 2.5 to 7.5 years of follow-up [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, the crude suicide rate in kidney transplant recipients from 1995 to 2001 was 24 per 100,000 patient-years, a finding that was 84 percent higher than the general population [<a href="#rid14">14</a>]. In multivariate models, age greater than 75 years, male sex, White or Asian race, geographic region, alcohol or drug dependence, and recent hospitalization with mental illness were significant independent predictors of death as a result of suicide.</p><p></p><p>In the kidney transplant population, depression occurs early after transplantation and is also associated with both acute and chronic rejection [<a href="#rid15">15</a>]. In one study, for example, patients with failed renal allografts were significantly more depressed, perceived less benefit from the treatment regimen, and had less confidence in their care providers than recipients of successful grafts [<a href="#rid10">10</a>].</p><p>Depression is also common in recipients of other organ transplants. Among heart transplant patients, for example, the incidence of depression was as high as 17 percent in the first posttransplant year [<a href="#rid16">16</a>].</p><p>The specific factors that increase a heart transplant recipient's risk for depression and anxiety-related disorders include the following [<a href="#rid16">16</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Pretransplant psychiatric history</p><p class="bulletIndent1"><span class="glyph">●</span>Poor social support</p><p class="bulletIndent1"><span class="glyph">●</span>The use of avoidance coping strategies for managing health problems</p><p class="bulletIndent1"><span class="glyph">●</span>Low self-esteem</p><p></p><p>Other factors that may lead to depression include the disfiguring effects of immunosuppressive medication, such as high-dose glucocorticoid therapy, and antihypertensive treatment with beta blockers. (See  <a class="medical medical_review" href="/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a> and  <a class="medical medical_review" href="/d/html/967.html" rel="external">"Major side effects of beta blockers"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Drug treatment</span><span class="headingEndMark"> — </span>Previously, therapeutic options for depression were hampered by the side effects associated with traditional agents. By comparison, newer antidepressant medications are more effective and safer in both the general population and medically ill patients [<a href="#rid17">17,18</a>]; however, there is little published data concerning their use in allograft recipients.</p><p>This diverse group of compounds possesses distinct pharmacokinetic properties which are unrelated to either the tricyclic/tetracyclic antidepressants or the monoamine oxidase inhibitors. These newer agents include selective serotonin reuptake inhibitors, such as <a class="drug drug_general" data-topicid="8465" href="/d/drug information/8465.html" rel="external">fluoxetine</a>, <a class="drug drug_general" data-topicid="9743" href="/d/drug information/9743.html" rel="external">paroxetine</a>, <a class="drug drug_general" data-topicid="9886" href="/d/drug information/9886.html" rel="external">sertraline</a>, <a class="drug drug_general" data-topicid="10013" href="/d/drug information/10013.html" rel="external">trazodone</a>, and <a class="drug drug_general" data-topicid="8474" href="/d/drug information/8474.html" rel="external">fluvoxamine</a>. Agents with serotonin reuptake activity that also prevent the uptake of other neurotransmitters (such as norepinephrine and dopamine) include <a class="drug drug_general" data-topicid="9684" href="/d/drug information/9684.html" rel="external">nefazodone</a>, <a class="drug drug_general" data-topicid="9171" href="/d/drug information/9171.html" rel="external">bupropion</a>, and <a class="drug drug_general" data-topicid="10042" href="/d/drug information/10042.html" rel="external">venlafaxine</a>.</p><p>One problem associated with the use of these agents may be drug interactions resulting in elevated calcineurin inhibitor levels due to alterations in the cytochrome CYP3A4 isoenzyme system [<a href="#rid19">19</a>].</p><p>However, it would be an oversimplification to suggest that a drug is metabolized by only one specific enzyme.</p><p>Caution therefore dictates that levels of affected drugs should be carefully monitored in any transplant patient who requires treatment for major affective disorders. Appropriate dosage adjustments should be performed as necessary to circumvent toxicity.</p><p class="headingAnchor" id="H1234197246"><span class="h1">BIPOLAR DISORDER</span><span class="headingEndMark"> — </span>Long-term <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a> use in some patients is associated with onset of chronic kidney disease, which may occasionally progress to end-stage kidney disease. (See  <a class="medical medical_review" href="/d/html/2358.html" rel="external">"Renal toxicity of lithium", section on 'Chronic interstitial nephritis and kidney function impairment'</a>.)</p><p>For patients with bipolar disorder who undergo kidney transplant as a result of end-stage kidney disease secondary to <a class="drug drug_general" data-topicid="9566" href="/d/drug information/9566.html" rel="external">lithium</a>, optimal maintenance pharmacotherapy for bipolar disorder is not clear. Using a drug other than lithium can put patients at risk for recurrences of major depression and mania, because alternative regimens may be less effective. Lithium has been used with caution after kidney transplantation, with the understanding that the nephrotoxic impact of lithium generally takes decades to manifest. There are few published data that describe the outcomes of lithium-treated bipolar patients after kidney transplantation.</p><p class="headingAnchor" id="H2787373423"><span class="h1">POSTTRAUMATIC STRESS DISORDER</span><span class="headingEndMark"> — </span>The evidence suggests that posttraumatic stress disorder (PTSD) is not a contraindication to kidney transplantation. As an example, a retrospective study of a nationally representative cohort of military veterans identified transplanted patients with a prior history of PTSD (n = 282) and a control group of transplanted patients without PTSD (n = 560) [<a href="#rid20">20</a>]. Patients were matched on variables such as age, type of donor, and comorbid diabetes; propensity scoring was used to match the two groups with regard to other observed potential confounders (eg, severity of general medical disorders, smoking status, and depression). The analyses found that all-cause mortality, death with functioning graft, and graft loss were each comparable for the group with PTSD and the controls. In addition, post-transplant medication adherence was comparable.</p><p class="headingAnchor" id="H5"><span class="h1">NONADHERENCE</span><span class="headingEndMark"> — </span>Nonadherence with diet and medication is a significant problem among some transplant recipients. This is due to numerous causes, including psychiatric disturbances, adverse effects of medications, lack of knowledge concerning the need for medications, and financial concerns [<a href="#rid21">21</a>]. This problem is particularly prevalent in children [<a href="#rid22">22</a>].</p><p>Nonadherence is one of the more important risk factors for acute rejection and graft loss [<a href="#rid23">23-28</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, the risk of acute graft rejection was 4.2 times greater among recipients who were not compliant with medications [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although the exact risk is difficult to assess, the odds of allograft failure may be seven-fold higher among noncompliant versus compliant patients [<a href="#rid26">26</a>].</p><p></p><p>Certain subgroups of transplant recipients have an enhanced risk of nonadherence [<a href="#rid10">10,21,29-32</a>]. One large study attempted to identify such risk factors in over 1400 patients who answered a questionnaire concerning whether they had missed one or more doses of immunosuppressive medications [<a href="#rid29">29</a>]. Multivariate analysis found that nonadherence was significantly associated with white collar occupations and a longer period of time elapsed since the transplantation, while compliance was most commonly observed among older patients and those who think that immunosuppressive drugs are highly important and exist in the body for only a short time.</p><p>An overview of the literature reported that certain patient characteristics were closely linked to nonadherence among solid organ transplant recipients [<a href="#rid33">33</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Younger and older age, and non-married</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anxious and individuals prone to denial, as well as those with severe personality disorders or intellectual disabilities</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of substance abuse</p><p></p><p>Additional factors underlying adherence include the particular transplant center and dosing frequencies of immunosuppressive medications, with higher dosing frequencies resulting in decreased adherence [<a href="#rid32">32,34</a>].</p><p>Retransplantation among patients with allograft loss due to adherence can be difficult to justify due to concerns of repeat noncompliance resulting in the loss of the second allograft. However, if properly rescreened, there is some evidence that retransplantation among such patients can be successful. In a single center retrospective study, the outcomes of patients who lost their initial allografts to noncompliance and underwent retransplantation after a thorough evaluation were compared with a control group of retransplant patients who did not lose their initial grafts to noncompliance [<a href="#rid35">35</a>]. At eight years, both groups had similar allograft and patient survival rates as well as incidence of chronic rejection.</p><p class="headingAnchor" id="H6"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/3439.html" rel="external">"Patient education: Heart transplantation (Beyond the Basics)"</a>) </p><p></p><p class="headingAnchor" id="H10376684"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Although follow-up of kidney donors shows that the majority of individuals express positive feelings about having donated a kidney, kidney recipients have difficulty asking a possible living donor to donate a kidney because of concerns about risking the health of a living donor, pain related to the donor surgery, and the possibility of kidney rejection. (See <a class="local">'Psychological impact of transplantation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>End-stage kidney disease and transplantation are associated with depression, which decreases adherence to treatment and may be associated with decreased longevity. Depression occurs early after transplantation and is associated with both acute and chronic rejection. (See <a class="local">'Depression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Depression is also common in recipients of other organ transplants. As an example, the incidence of depression among heart transplant patients is 17 percent in the first posttransplant year. Risk factors that increase a heart transplant recipient's risk for depression and anxiety disorders include pretransplant psychiatric history, poor social support, using avoidance coping strategies for managing health problems, and poor self-esteem. (See <a class="local">'Depression'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Selective serotonin reuptake inhibitors are often used to treat depression, but may interact with and increase calcineurin inhibitor serum concentrations. (See <a class="local">'Drug treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transplant recipients may not adhere to their prescribed diet and medications, which may lead to acute rejection and graft loss. Risk factors for poor adherence include psychiatric problems, adverse effects of medications, higher dosing frequency of medications, lack of knowledge concerning the need for medications, financial concerns, white collar occupations, and a longer period of time elapsed since the transplantation. (See <a class="local">'Nonadherence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We encourage you to print or e-mail the patient information topic on heart transplantation. (See  <a class="medical medical_patient" href="/d/html/3439.html" rel="external">"Patient education: Heart transplantation (Beyond the Basics)"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Stewart RS. Psychiatric issues in renal dialysis and transplantation. Hosp Community Psychiatry 1983; 34:623.</a></li><li><a class="nounderline abstract_t">Sher Y, Zimbrean P. Psychiatric Aspects of Organ Transplantation in Critical Care: An Update. Crit Care Clin 2017; 33:659.</a></li><li><a class="nounderline abstract_t">Sharma VK, Enoch MD. Psychological sequelae of kidney donation. A 5-10 year follow up study. Acta Psychiatr Scand 1987; 75:264.</a></li><li><a class="nounderline abstract_t">Schover LR, Streem SB, Boparai N, et al. The psychosocial impact of donating a kidney: long-term follow-up from a urology based center. J Urol 1997; 157:1596.</a></li><li><a class="nounderline abstract_t">Fehrman-Ekholm I, Elinder CG, Stenbeck M, et al. Kidney donors live longer. Transplantation 1997; 64:976.</a></li><li><a class="nounderline abstract_t">Bunzel B, Wollenek G, Grundböck A. Living with a donor heart: feelings and attitudes of patients toward the donor and the donor organ. J Heart Lung Transplant 1992; 11:1151.</a></li><li><a class="nounderline abstract_t">Waterman AD, Stanley SL, Covelli T, et al. Living donation decision making: recipients' concerns and educational needs. Prog Transplant 2006; 16:17.</a></li><li><a class="nounderline abstract_t">Pradel FG, Limcangco MR, Mullins CD, Bartlett ST. Patients' attitudes about living donor transplantation and living donor nephrectomy. Am J Kidney Dis 2003; 41:849.</a></li><li><a class="nounderline abstract_t">McCabe MS, Corry RJ. Psychiatric illness and human renal transplantation. J Clin Psychiatry 1978; 39:293.</a></li><li><a class="nounderline abstract_t">Kiley DJ, Lam CS, Pollak R. A study of treatment compliance following kidney transplantation. Transplantation 1993; 55:51.</a></li><li><a class="nounderline abstract_t">Devins GM, Beanlands H, Mandin H, Paul LC. Psychosocial impact of illness intrusiveness moderated by self-concept and age in end-stage renal disease. Health Psychol 1997; 16:529.</a></li><li><a class="nounderline abstract_t">Dobbels F, Skeans MA, Snyder JJ, et al. Depressive disorder in renal transplantation: an analysis of Medicare claims. Am J Kidney Dis 2008; 51:819.</a></li><li><a class="nounderline abstract_t">Washer GF, Schröter GP, Starzl TE, Weil R 3rd. Causes of death after kidney transplantation. JAMA 1983; 250:49.</a></li><li><a class="nounderline abstract_t">Kurella M, Kimmel PL, Young BS, Chertow GM. Suicide in the United States end-stage renal disease program. J Am Soc Nephrol 2005; 16:774.</a></li><li><a class="nounderline abstract_t">Hilbrands LB, Hoitsma AJ, Koene RA. The effect of immunosuppressive drugs on quality of life after renal transplantation. Transplantation 1995; 59:1263.</a></li><li><a class="nounderline abstract_t">Dew MA, Roth LH, Schulberg HC, et al. Prevalence and predictors of depression and anxiety-related disorders during the year after heart transplantation. Gen Hosp Psychiatry 1996; 18:48S.</a></li><li><a class="nounderline abstract_t">Andrews JM, Nemeroff CB. Contemporary management of depression. Am J Med 1994; 97:24S.</a></li><li><a class="nounderline abstract_t">Stoudemire A. New antidepressant drugs and the treatment of depression in the medically ill patient. Psychiatr Clin North Am 1996; 19:495.</a></li><li><a class="nounderline abstract_t">DeVane CL. Pharmacokinetics of the newer antidepressants: clinical relevance. Am J Med 1994; 97:13S.</a></li><li><a class="nounderline abstract_t">Siwakoti A, Potukuchi PK, Thomas F, et al. History of posttraumatic stress disorder and outcomes after kidney transplantation. Am J Transplant 2019; 19:2294.</a></li><li><a class="nounderline abstract_t">Butler JA, Peveler RC, Roderick P, et al. Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study. Nephrol Dial Transplant 2004; 19:3144.</a></li><li><a class="nounderline abstract_t">Rosenthal JT, Danovitch G, Ettenger RB, Wilkinson A. Kidney transplantation at UCLA. Clin Transpl 1990; :255.</a></li><li><a class="nounderline abstract_t">Smith AY, Van Buren CT, Lewis RM, et al. Factors determining renal transplant outcome at the University of Texas at Houston. Clin Transpl 1987; :155.</a></li><li><a class="nounderline abstract_t">Burke G, Esquenazi V, Gharagozloo H, et al. Long-term results of kidney transplantation at the University of Miami. Clin Transpl 1989; :215.</a></li><li><a class="nounderline abstract_t">Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002; 62:704.</a></li><li><a class="nounderline abstract_t">Butler JA, Roderick P, Mullee M, et al. Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004; 77:769.</a></li><li><a class="nounderline abstract_t">Vlaminck H, Maes B, Evers G, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant 2004; 4:1509.</a></li><li><a class="nounderline abstract_t">Dew MA, Kormos RL, Roth LH, et al. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. J Heart Lung Transplant 1999; 18:549.</a></li><li><a class="nounderline abstract_t">Greenstein S, Siegal B. Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study. Transplantation 1998; 66:1718.</a></li><li><a class="nounderline abstract_t">Abbott KC, Agodoa LY, O'Malley PG. Hospitalized psychoses after renal transplantation in the United States: incidence, risk factors, and prognosis. J Am Soc Nephrol 2003; 14:1628.</a></li><li><a class="nounderline abstract_t">Shaw RJ, Palmer L, Blasey C, Sarwal M. A typology of non-adherence in pediatric renal transplant recipients. Pediatr Transplant 2003; 7:489.</a></li><li><a class="nounderline abstract_t">Weng FL, Israni AK, Joffe MM, et al. Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation. J Am Soc Nephrol 2005; 16:1839.</a></li><li><a class="nounderline abstract_t">Bunzel B, Laederach-Hofmann K. Solid organ transplantation: are there predictors for posttransplant noncompliance? A literature overview. Transplantation 2000; 70:711.</a></li><li><a class="nounderline abstract_t">Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353:487.</a></li><li><a class="nounderline abstract_t">Dunn TB, Browne BJ, Gillingham KJ, et al. Selective retransplant after graft loss to nonadherence: success with a second chance. Am J Transplant 2009; 9:1337.</a></li></ol></div><div id="topicVersionRevision">Topic 4850 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6350150" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Psychiatric issues in renal dialysis and transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28601140" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Psychiatric Aspects of Organ Transplantation in Critical Care: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3296664" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Psychological sequelae of kidney donation. A 5-10 year follow up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9112484" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The psychosocial impact of donating a kidney: long-term follow-up from a urology based center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9381544" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Kidney donors live longer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1457439" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Living with a donor heart: feelings and attitudes of patients toward the donor and the donor organ.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16676669" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Living donation decision making: recipients' concerns and educational needs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12666072" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Patients' attitudes about living donor transplantation and living donor nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/346583" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Psychiatric illness and human renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8420064" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A study of treatment compliance following kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386998" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Psychosocial impact of illness intrusiveness moderated by self-concept and age in end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18436093" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Depressive disorder in renal transplantation: an analysis of Medicare claims.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6343652" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Causes of death after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15659561" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Suicide in the United States end-stage renal disease program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7762059" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The effect of immunosuppressive drugs on quality of life after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937923" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence and predictors of depression and anxiety-related disorders during the year after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992823" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Contemporary management of depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8856814" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : New antidepressant drugs and the treatment of depression in the medically ill patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7992822" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pharmacokinetics of the newer antidepressants: clinical relevance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30672107" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : History of posttraumatic stress disorder and outcomes after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15479748" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Modifiable risk factors for non-adherence to immunosuppressants in renal transplant recipients: a cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2103151" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Kidney transplantation at UCLA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3154393" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Factors determining renal transplant outcome at the University of Texas at Houston.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2487568" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term results of kidney transplantation at the University of Miami.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12110036" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Five preventable causes of kidney graft loss in the 1990s: a single-center analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15021846" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15307839" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10395353" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9884266" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Compliance and noncompliance in patients with a functioning renal transplant: a multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12761265" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Hospitalized psychoses after renal transplantation in the United States: incidence, risk factors, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14870900" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A typology of non-adherence in pediatric renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800121" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Race and electronically measured adherence to immunosuppressive medications after deceased donor renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11003346" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Solid organ transplantation: are there predictors for posttransplant noncompliance? A literature overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16079372" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Adherence to medication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19459828" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Selective retransplant after graft loss to nonadherence: success with a second chance.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
